

Review

# Novel Development of Nanoparticles—A Promising Direction for Precise Tumor Management

Dengke Zhang <sup>1,†</sup>, Qingqing Tang <sup>1,†</sup>, Juan Chen <sup>2</sup>, Yanghui Wei <sup>1,\*</sup> and Jiawei Chen <sup>1,\*</sup> <sup>1</sup> Department of Surgery, The Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510275, China<sup>2</sup> Department of Medicine & Rehabilitation, Tung Wah Eastern Hospital, Hong Kong, China

\* Correspondence: weiyh23@mail.sysu.edu.cn (Y.W.); chenjw288@mail.sysu.edu.cn (J.C.)

† These authors contributed equally to the work.

**Abstract:** Although the clinical application of nanoparticles is still limited by biological barriers and distribution, with the deepening of our understanding of nanoparticles over the past decades, people are gradually breaking through the previous limitations in the diagnosis and treatment of tumors, providing novel strategies for clinical decision makers. The transition of nanoparticles from passive targeting to active tumor-targeting by abundant surface-modified nanoparticles is also a development process of precision cancer treatment. Different particles can be used as targeted delivery tools of antitumor drugs. The mechanism of gold nanoparticles inducing apoptosis and cycle arrest of tumor cells has been discovered. Moreover, the unique photothermal effect of gold nanoparticles may be widely used in tumor therapy in the future, with less side effects on surrounding tissues. Lipid-based nanoparticles are expected to overcome the blood–brain barrier due to their special characteristics, while polymer-based nanoparticles show better biocompatibility and lower toxicity. In this paper, we discuss the development of nanoparticles in tumor therapy and the challenges that need to be addressed.

**Keywords:** nanoparticles; tumor-targeting; antitumor drug



**Citation:** Zhang, D.; Tang, Q.; Chen, J.; Wei, Y.; Chen, J. Novel Development of Nanoparticles—A Promising Direction for Precise Tumor Management. *Pharmaceutics* **2023**, *15*, 24. <https://doi.org/10.3390/pharmaceutics15010024>

Academic Editors: Alexander Zaboronok, Bryan J. Mathis and Andrea Lancia

Received: 27 October 2022

Revised: 4 December 2022

Accepted: 9 December 2022

Published: 21 December 2022



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction


Among cancer treatment strategies, surgery, radiotherapy, chemotherapy, and immunotherapy are the most basic methods. With the continuous standardization and promotion of cancer treatment plans, the overall mortality of cancer has a downward trend; the 29% overall mortality rate of cancer decreased compared with the peak in 1991, but the total number of deaths is still large, with 609,360 cancer deaths being estimated to occur in America in 2022 [1]. The large number of cancer-associated mortalities is partly due to the imprecision of therapeutic methods and the caused side effects. For example, during radiotherapy, radiation can induce pneumonitis and dermatitis from damaging the healthy surrounding tissues; during systemic chemotherapy, normal tissues such as mucosal epithelium and bone-marrow hematopoietic tissues will be greatly affected because chemotherapy drugs cannot distinguish malignant cells from those cells [2]. This will lead to a decline in the therapeutic effect. Regarding this, more studies on tumor-targeting nanoparticles are warranted to provide new strategies for cancer treatment.

## 2. Targeting Mechanism of Nanoparticles

### 2.1. Passive Targeting of Nanoparticles

Molecules at the nanometer scale endow nanoparticles with a special property, which is the enhanced permeability and retention (EPR) effect [3]. For solid tumors, the capillary plexus in them is abnormal and disorganized; the density of these capillaries is increased, with significantly increased permeability, which allows nanoparticles with a molecular diameter of 100–800 nm to enter tumor tissue [4]. In contrast, the nutrient vascular endothelium of normal

tissue is closely arranged. Meanwhile, the clearing function of lymphatic vessels in tumor tissue is impaired, causing a long-term retention of nanoparticles, which is one of the reasons for tumor immune escape [5]. As shown in Figure 1 below, the difference in the arrangement of vascular endothelial cells between tumor tissue and normal tissue results in this special property of tumor. However, this targeting mechanism is limited by the biological distribution *in vivo*, the nonspecific uptake of normal tissues, the degree of tumor vascularization, and the blood vessel flow. In the plasma environment of circulation, nanoparticles are adsorbed and opsonized by albumin, complement components, immunoglobulins, and other plasma proteins and subsequently internalized by the mononuclear phagocytic system (MPS), mainly in the liver, lymph nodes, and spleen [6]. It is suggested that nanoparticles that are 100–200 nm in size have an excellent EPR effect, which can also help them avoid the filter trap of liver and spleen to the greatest extent [5]. Moreover, for pancreatic ductal adenocarcinoma characterized by insufficient vascularization and nonsolid tumors, it is hard to target nanoparticles toward tumor cells [7].



**Figure 1.** Compared with the tumor tissue in (B), the nutrient vascular epithelial cells in the normal tissue in (A) are arranged very closely, and only small molecules are easy to pass through; however, in (B), nanoparticles with a molecular diameter of 100–800 nm can smoothly pass through the nutrient vessels into the tumor tissue [4]. Moreover, there are few lymphoid tissues or only drainage-damaged lymphatic vessels in the tumor tissue, and the nanoparticles' clearance will also be reduced [5].

## 2.2. Active Tumor-Targeting Mechanism of Nanoparticles

Many receptors, such as epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), and folic acid receptors, which belong to normal cells were thriving, expressed in the surface of tumor cells; in addition, specific landmark polypeptides and proteins are also expressed on the surface. Therefore, these sites become targets for modified nanoparticles by corresponding ligands to “track” tumor cells. The following categories are the main identified targets.

### 2.2.1. Human Epidermal Growth Factor Receptors (HERs)

HERs are tyrosine-kinase-coupled receptors which belong to the erythroblastic leukemia oncogene B family, mediating normal cell proliferation, tumor progression, and invasion [8]. HER1, also known as epidermal growth factor receptors (EGFRs), is overexpressed especially in non-small cell lung cancer [9]. HER2 is another member of this family. HER2 overexpression is estimated to occur in 15% to 30% of breast cancers and in about 10% to 30% gastric cancers. HER2 expression suggests a bad clinical outcome, which also makes it an attractive target for treatment and nanoparticles' engineering design [10].

### 2.2.2. Vascular Endothelial Growth Factor Receptors (VEGFRs)

The growth process of most solid tumors is accompanied by abnormal neovascularization, with vascular endothelial growth factors (VEGFs) induced by the hypoxic microenvironment in tumor [11]. In addition to the vasogenic role of VEGF/VEGFR, there is evidence that VEGFR 1 is involved in the colorectal carcinoma cells' metastasis [11].

Moreover, VEGF/VEGFR inhibits the function of T lymphocytes and participates in the immune escape of tumors [12], making it a target of anticancer treatment.

### 2.2.3. Fibroblast Growth Factor Receptors (FGFRs)

Fibroblast growth factor and its receptors regulate various functions, such as migration, proliferation, and differentiation of wide range cell types in healthy tissue [13]. In the major steps of tumor progression, such as angiogenesis, invasion, and metastasis of germ-cell neoplasms [14], breast cancer [15], and bladder cancer [16], the FGF/FGFR signal is excessive, suggesting that it is a potential anticancer target. In the US, two FGFR inhibitors, Erdafitinib [17] and Pemigatinib [18], have been approved in recent years for the treatment of metastatic urothelial carcinoma and unresectable cholangiocarcinoma, respectively.

### 2.2.4. Nutrition-Related Receptors

The rapid proliferation of tumor cells often requires excessive nutrients, including albumin, folic acid, and iron. Albumin internalization relies on the binding with high affinity to the gp60 receptor on the surface of tumor endothelial cells, and the overexpression of secreted protein acidic rich in cysteine (SPARC) in different type of tumors also attracts albumin, promoting albumin accumulation inside the tumor cells [19]. Folic acid receptors are expressed in aggressive cancers, including ovarian cancer, breast cancer, and uterine adenocarcinoma, more than in normal tissue cells [20–23]. To meet the iron requirements of tumor cells, transferrin receptors are often expressed up to 10 times as much as normal tissues [24]. Albumin and transferrin can be used as ligands for drug targeting delivery with good biocompatibility. In addition, transferrin is a potential ligand which enables nanoparticles to cross the blood–brain barrier (BBB) and target glioma cells [25]. In pancreatic ductal adenocarcinoma (PDAC) progression, PDAC-derived cancer-associated fibroblasts (CAFs), which mediate peritumoral fibrosis and the creation of the drug physical barrier, are highly dependent on SLC7A11 for cystine uptake and glutathione synthesis; related experiments showed that the nanogene-silencing drug treatment against SLC7A11 inhibited the growth and metastasis of PDAC, CAF activation, and fibrosis [26].

### 2.2.5. Tumor Specific Antigen, Protein and Peptide Receptor

Specific amino acid sequence composition on the tumor surface, including several receptors described above, can be recognized by B lymphocytes, and they then stimulate B cells to produce monoclonal antibodies with high affinity to tumors. In clinical settings, Perjeta and Herceptin targeting HER2 have been widely used in HER2 overexpressed breast cancer and gastric adenocarcinoma and have achieved excellent clinical results [27]. Nanoparticles binding with monoclonal antibodies can efficiently target tumors.

In the next part of this review, we focus on different kinds of nanoparticles and the potential of novel application scenarios they have shown in recent years.

## 3. Inorganic Nanoparticles

Many studies reported the role and potential of inorganic nanoparticles in oncology; this class of NP usually has unique physical characteristics, such as unique optical, electrical, thermal, and magnetic properties, which lead to their extensive applications in tumor diagnosis and treatment. Among them, Au nanoparticles and carbon nanoparticles are the most extensively studied nanoparticles.


### 3.1. Au Nanoparticles

As one of the most stable and least toxic metal NP formulations, Au NPs are widely used as a cancer-targeted drug-delivery system. D-P-HGNPs/21 is a sequential drug-delivery system which enters the tumor cells through the endocytic pathway and first releases MiR-21i when it reaches the tumor. Near-infrared-radiation triggers the collapse of hollow Au NPs to achieve Dox release. Moreover, two different breast cancer cell experiments showed that the D-P-HGNPs/21 sequential release system has a more effective

inhibitory effect on tumor growth [28]. As a carrier of doxorubicin (Dox), Au NPs coupled with prostate-specific membrane antigen (PSMA) aptamer could specifically bind to target prostate cancer cells that overexpressing PSMA antigen. Dongkyu Kim et al. combined Au NPs, dox, and PSMA aptamer together, and then they observed that the assembled Au NPs complex were significantly more potent against targeted LNCaP cells that overexpressed PSMA antigen than against nontargeted PC3 cells that did not express detectable PSMA [29]. Daiki et al. conducted a similar study in 2021, confirming the targeting ability to LNCaP cells of this assembled Au NPs complex [30], and it was concluded that PSMA aptamer coupling Au NPs with adriamycin could kill LNCaP cancer cells more effectively than nontargeting PC3 cells [29]. In addition, Au-NPs-mediated gene therapy may significantly promote the improvement of anticancer therapy, and using Au NP compositions for effective RNAi delivery to silence protooncogene is a promising strategy for tumor treatment [31]. The experiments of Conde et al. in human cell models *in vitro* and vertebrate models have proved that this strategy can silence the *c-myc* protooncogene [32]. Although there are many advantages to gene therapy, drug delivery, and the photothermal triggered release based on gold nanoparticles, the results need further analysis and research to obtain practical results [31]. Gold nanoparticles coated with protein have also attracted people's attention due to their excellent biocompatibility. Lysozyme-coated AuNPs synthesized by chemical reduction and collagen-coated AuNPs synthesized by the chemical reduction method were internalized efficiently by MG-63 osteosarcoma cells; thus, these two effectively absorbed coated nanoparticles may be used as diagnostic and therapeutic agents for osteosarcoma [33].

In addition, many studies have revealed that the photothermal effect of Au nanoparticles (Au NPs) and their composite nanoparticles is promising in the clinical application of tumor therapy [34]. Au NPs possess a surface plasmon resonance (SPR) effect, high biocompatibility, and stability *in vivo*; Au NPs are also ideal photothermal conversion materials for increasing optical absorption directly [35]. *In vitro* infrared ray and laser irradiation on the tumor area can directly kill tumor cells by causing local high heat through the accumulation of photothermal conversion agents (PTAs), such as Au NPs in the tumor [36]. This was called photothermal therapy (PTT); PTT induces less damage to normal tissues due to the fact that cancer cells are more intolerant to heat compared with normal cells [37]. However, there are some drawbacks that impair the clinical result of PTT, such as inadequate tumor accumulation, low photothermal conversion efficiency, and the poor stability of PTAs [38]. Polydopamine (PDA)-coated Au-Ag NPs improve the photothermal efficiency by shifting the SPR peak to the 808 nm wavelength, which matches the most used laser in photothermal therapy [39], and PDA coating can improve biocompatibility, increase hydrophilicity, and reduce cytotoxicity [40]. However, the thermal effect of PDA-coated NPs and the excessive accumulation of PDA-coated NPs localized to lysosomes and mitochondria cause lysosomal dysfunction and oxidative stress, which can induce the autophagy of tumor cells and protect tumor cells from external stimulation to a certain extent [41,42]. Wang et al. found that tumor cells pretreated with the autophagy inhibitor chloroquine showed higher mortality, which also provide evidence to support this point of view [43]. Although autophagy has a tumor-protective effect to a certain extent, PDA-coated Au-Ag NPs still show a strong ability to kill tumor cells. *In vitro* cultured bladder cancer T24 cells showed that PDA-coated branched Au-Ag NPs could induce cell-cycle arrest and apoptosis of tumor cells through various mechanisms, and T24 cells treated with PDA-coated branched Au-Ag NPs could induce S phase arrest, which was associated with decreased cyclin A level and increased p21 level [44]. Cyclin A is protein involved in the initiation and termination of S-phase DNA replication in the nuclear [45]; p21 inhibits cell-cycle progression by inhibiting the activity of cyclin-dependent kinases [46]; and, consequently, T24 cells will undergo S-phase arrest. Moreover, Au-Ag NPs are also involved in intrinsic pathways' induced apoptosis of tumor cells, and the BCL2 family controls the permeability of mitochondrial membrane [47]; PDA-coated branched Au-Ag NPs decreased the BCL2 level, which further led to the depolarization of mitochondrial membrane potential ( $\Delta\Psi_m$ )

and the subsequent release of cytochrome c into the cytoplasmic matrix. This will activate caspase-8 and caspase-3 to trigger apoptosis in T24 cells [44]. In a xenograft mouse model treated by laser irradiation after the injection of high-dose NPs, tumor growth was significantly suppressed [44]. After 12 days of PTT, the cell morphology of the heart, spleen, and liver in mice did not change significantly, while the tumor cells showed significant nuclear lysis, suggesting the low toxicity of Au NPs to normal cells and specific high toxicity to cancer cells [44]. In addition, the mitochondrial accumulation of PDA-coated Au-Ag NPs in in vitro thyroid cancer cell models led to the inhibition of dihydroorotate dehydrogenase (DHODH) expression, followed by enhanced transcriptional activity of the p53 gene, and it induced the S-phase arrest of tumor cells [48]. The Figure 2 below shows the mechanisms of tumor proliferation cycle arrest and apoptosis induced by PDA-coated Au-Ag NPs under laser irradiation. Similarly, pH-responsive AuNPs (CytC/ssDNA-AuNP), by introducing a mixed layer of single-stranded DNA and cytochrome c, forms clustered particle clusters in acidic environments and thus has a low pH-specific high photothermal efficiency on near-infrared radiations [49]. These pH-responsive AuNPs can be employed for cancer targeted therapy and improve its photothermal conversion efficiency in PTT based on the acidic tumor microenvironment [50]. More importantly, the pH response behavior mechanism based on electrostatic interactions between particles makes it possible to reversibly aggregate or disassemble particle clusters according to the solution pH, suggesting that the CytC/ssDNA-AuNP has the potential to exert its therapeutic effect on lesions repeatedly [49].



**Figure 2.** Mechanism of laser-irradiation-induced proliferation arrest and apoptosis of PDA-coated-Au-Ag-NP-treated tumor cells. In tumor cells, PDA-coated Au-Ag NPs increase the p21 level, which inhibits the activity of cyclin-dependent kinases, and decrease the Cyclin A level, which plays an important role in the initiation and termination of S-phase DNA replication at the nuclear. In addition, the mitochondrial accumulation of PDA-coated Au-Ag NPs leads to the inhibition of DHODH expression, followed by enhanced transcriptional activity of p53 gene, an important tumor-suppressor gene. All of these together will result in the S-phase arrest of tumor cells. The BCL2 family controls the permeability of mitochondrial membrane. PDA-coated branched Au-Ag NPs induced the decrease of BCL2 level, which further led to the depolarization of mitochondrial membrane potential ( $\Delta\Psi_m$ ) and the subsequent release of cytochrome c into the cytoplasmic matrix; this activates caspase-8 and caspase-3, which then trigger cell apoptosis.

### 3.2. Carbon Nanoparticles

Carbon has many nano-allotropic forms, including fullerenes, nanotubes, and nanodiamonds. Their rich forms bring them many possibilities in tumor recognition, treatment, and drug delivery [51]. However, the hydrophobicity of carbon nanoparticles limits their medical application. This problem can be solved to some extent by modifying hydrophilic groups on the surface of carbon nanoparticles, and the toxicity of carbon nanoparticles can be reduced at the same time [52,53]. Paclitaxel (PTX) is a commonly used chemotherapy drug for breast cancer, and the effect is affected by poor water solubility; thus, albumin-bound PTX is the common dosage form in the clinic to improve its water solubility [54]. Shao et al. [55] found that when human serum albumin (HSA)-modified single-walled carbon nanotubes (SWCNTs), namely SWCNT-HSA complex, were used as a carrier for delivering PTX, the cell uptake rate of MCF-7 breast cancer cells could reach 80%, and this complex showed a stronger antitumor effect than has-modified PTX. Diamond nanoparticles (NDs) have high biocompatibility and low toxicity to normal cells; they can also form complexes with poorly water-soluble chemotherapeutic agents [56]. The existence of the BBB is a huge obstacle in the treatment of malignant brain tumors [57]. Liang et al. suggested NDs labeled by PEGylated denatured bovine serum albumin (BSA), and tumor vasculature-targeting tripeptides RGD, which is dcBSA-PEG-NDs, showed high efficiency in selectively targeting tumor sites in U-87 MG-bearing mice through the BBB [58]; *in vitro* BBB models revealed that the transcytosis mechanism and an additional direct cell–cell transport via tunneling nanotubes are both involved in this process [59]. One way to silence defective genes is by delivering interfering RNA (siRNA) into tumor cells. However, the instability of siRNA and low uptake of tumor cells limit its application, but *in vitro* experiments of MCF-7 breast cancer cells suggested that modified NDs could be made into a complex with siRNA for more efficient delivery of siRNA to tumor cells and silencing the expression of defective genes [60].

Another application of carbon nanomaterials is to identify tumor tissues and normal tissues during surgery, as well as lymph nodes' draining from tumor areas. Thyroid cancer is the most pervasive endocrine malignancy, with its incidence increasing dramatically in recent decades, and papillary thyroid cancer (PTC) is the major contributor, as it accounts for 85% to 90% of all thyroid cancers [61]. According to the data from 1994 to 2013, at least 28.6% of PTCs had tumors with a diameter of 1 cm or less, which is called papillary thyroid microcarcinomas (PTMCs) [62]. The standard surgical procedure for PTC is total thyroidectomy and appropriate lymph-node dissection; the main risks of this surgery are parathyroid damage and recurrent laryngeal nerve damage [63]. Carbon nanomaterials with a diameter of 150 nm enter lymphatic vessels and then are transported to regional lymph nodes, but they do not enter blood vessels [64]. The intertumoral injection of carbon nanomaterials to stain tumor tissues and regional lymph nodes to protect parathyroid tissues has been widely used [65]. However, recent research revealed that the intertumoral injection of carbon nanomaterials cannot decrease the incidence of hypoparathyroidism, and this may be associated with the fact that the parathyroid glands possess compensatory potential [64]. For low-risk endometrial cancer patients, clinical trials have confirmed that cervical injection of carbon nanoparticles combined with indocyanine green can significantly improve the detection rate of sentinel lymph nodes (SLNs) [66]. In patients undergoing laparoscopic radical gastric cancer surgery, those who received carbon nanomaterials labeling can increase the lymph node discovery rate by 25.7% and shorten the operation time by 15.3% compared with the control group [67]. PTMCs are considered low-risk cancers. As one of the most attractive techniques, thermal ablation (TA) has achieved great success in many malignant diseases, including liver cancer and kidney cancer. In recent years, this technology has been gradually introduced into the treatment of PTMCs and even PTCs [68], the effect of microwave ablation was satisfactory, and the tumor volume reduction rate (VRR) reached or even exceeded 99% [69]. Compared with conventional open surgical methods, the incidence of complications is relatively low, and the difference between the recurrence rates was not statistically significant [69]. However, microwave ablation still

has a certain risk of damaging the surrounding tissue. Experiments in mice receiving thyroid cancer TPC-1 xenotransplantation showed that the intertumoral injection of carbon nanomaterials can absorb near-infrared light, converting light into heat and achieving a temperature of 50–56 °C in the tumor; this is sufficient to kill tumor cells, thus avoiding systemic toxicity and protecting the parathyroid gland because the carbon nanomaterials act only on tumor tissue [70]. This suggests that the application of the photothermal effect of carbon nanomaterials in thyroid cancer is a promising direction in the future.

### 3.3. Lipid-Based Nanoparticles

Lipid-based nanobiomaterials, the most widely studied anticancer drug-delivery systems, are vesicular structures consisting of a single lipid bilayer that encases the anticancer drug in its hydrophilic core [71]. Lipid-based nanobiomaterials mainly include liposomes, nanoemulsions, lipid nanoparticles (LNPs), and solid lipid nanoparticles (SLNs), which offer many advantages, such as easy fabrication, the ability to self-assemble in aqueous media, enhanced bioavailability, biocompatibility, biodegradability of major components, low toxicity, and the ability to carry hydrophilic and hydrophobic compounds [72]. In addition, the main problems that this type of drug-delivery system faces are how to increase their stability, how to increase the residence time in circulation, and how to improve the efficiency of delivery of the drug or nucleic acid molecules to the target cells [73]. PEGylated liposomes, or long-circulating (stealth) liposomes, are liposomes modified and functionalized with hydrophilic polymer chains, including polyethylene glycol (PEG), polyethylene oxide (PEO), poloxamer, poloxamine, polysorbate (Tween-80), and lauryl ethers (Brij-35); this can effectively increase their residence time in circulation [74]. Lipid-based drug-delivery systems function in two ways: One way is active targeting, as described previously, by targeting specific sites, coupling liposomes to ligands that could bind to specific target cell receptors [75]. The other way is passive targeting, which is realized through EPR effect [73]. Different schemes can be designed to alter the average nanometer size, homogeneity, surface potential, drug loading, and ligand type of lipid-based nanoparticles to enhance their drug-delivery efficiency to the targeted cells [76,77]. Research in recent decades has put various liposome formulations into biomedical applications or clinical trials after overcoming the abovementioned shortcomings, as is shown in Table 1 below.

**Table 1.** Current lipid nanoparticles for cancer treatment and drug regimens being studied in clinical trials. Date from [ClinicalTrials.gov](https://clinicaltrials.gov).

Nanoparticle Formulation and Combination Drug Regimen	Type of Cancer	Clinical Trial ID	Phase
Liposomal doxorubicin combination with anti-CD47, ALX148, and pembrolizumab	Recurrent Platinum-Resistant Ovarian Cancer	NCT05467670	2
Lyso-thermosensitive liposomal doxorubicin (LTLTD)	Relapsed/refractory solid tumors in children	NCT02536183	1
Liposome-encapsulated daunorubicin–cytarabine	Refractory Acute Myeloid Leukemia	NCT04049539	2
PEGylated liposomal doxorubicin and SL-172154	Ovarian cancers	NCT05483933	1
Lysosomal-associated membrane protein (LAMP) mRNA-loaded DOTAP liposome vaccine	Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)	NCT04573140	1
Liposomal HPV-16 E6/E7 multi-peptide vaccine PDS0101	Oropharyngeal carcinoma	NCT05232851	1
PEGylated liposomal doxorubicin hydrochloride	Female reproductive system tumors	NCT04092270	1
Nanoliposomal irinotecan combine with trifluridine and tipiracil hydrochloride	Advanced gastrointestinal cancer	NCT03368963	2
PEGylated liposomal doxorubicin (PLD)	Advanced solid malignancies	NCT04244552	1

Table 1. Cont.

Nanoparticle Formulation and Combination Drug Regimen	Type of Cancer	Clinical Trial ID	Phase
Liposomal Bcl-2 antisense oligodeoxynucleotide	Relapsing acute myeloid leukemia	NCT05190471	1
Vincristine sulfate liposome	Acute lymphoblastic leukemia	NCT02879643	1
Liposome-encapsulated daunorubicin–cytarabine	Advanced myeloproliferative neoplasms	NCT03878199	2
Irinotecan liposome and bevacizumab	Platinum-resistant fallopian tube, ovarian, primary peritoneal carcinoma	NCT04753216	2
Liposome-encapsulated daunorubicin–cytarabine combine with gemtuzumab ozogamicin	Relapsed or refractory acute myeloid leukemia (AML)	NCT03672539	2
BP1001-A (liposomal Grb2 antisense oligonucleotide)	Advanced or recurrent solid tumors	NCT04196257	1
CDX-301 and CDX-1140 in combination with PEGylated liposomal doxorubicin (PLD, Doxil)	Metastatic triple negative breast cancer	NCT05029999	1
liposomal irinotecan (nanoliposomal irinotecan (Nal-IRI))	Neuroendocrine neoplasms of the digestive tract	NCT03736720	2

### 3.3.1. Advances in Multifunctional Lipid-Based Nanobiomaterials

Liposomes have been widely used to combine different therapeutic classes of anti-cancer drugs for chemotherapy and immunotherapy, gene therapy, photochemotherapy, etc. Liposomal doxorubicin (Doxil) is the first therapeutic nanoparticle to receive clinical approval for cancer therapy using PEGylated liposome, laying the foundation for intensive research in nanotechnology for tumor-targeted drugs [78]. Moreover, subsequently, many liposomal formulations for anticancer drug delivery have successfully entered clinical trials.

### 3.3.2. New Therapeutic Techniques Involving Lipid-Based Nanobiomaterials

Recently, attention has been drawn to the study of natural liposomes. Exosomes, as membrane vesicles with a diameter of 30–100 nm, have a double lipid membrane with the same origin pathway as the plasma membrane, containing proteins and genetic material that play an important role in intercellular communication inside [79]. Due to their inherent excellent properties, including their wide distribution in biological fluids, inherent homing ability, and the ability to penetrate the BBB, exosomes can undoubtedly be ideal drug-delivery carriers [80]. For example, exosomes isolated from MSCs can be used as drug nanocarriers to load the paclitaxel (PTX) for pancreatic cancer treatment [81]; exosomes isolated from mouse immature dendritic cells (imDC) can be used to load the doxorubicin (Dox) for breast cancer treatment [82].

In addition to this, attempts have been made to unite multiple nanocarriers so as to overcome their respective drawbacks without compromising their original properties. Lipid–polymer hybrid nanoparticle (LPHNP) systems can be a robust drug-delivery podium with high encapsulation efficiency; defined release kinetics; excellent tolerable serum stability; and well-triggered tissue-, cellular-, and molecular-targeting properties [83]. In 2010, Wang et al. proposed an LPHNP for prostate cancer models, named ChemoRad NP, intended for the codelivery of chemotherapeutics and therapeutic radioisotopes; this platform is mainly composed of two parts, the polylactic-co-glycolic acid (PLGA) polymeric core, which encapsulates chemotherapeutic agent (docetaxel), and the DMPE-DTPA lipid chelator layer, which chelates radiotherapeutic agent (indium-111 or yttrium-90); they demonstrated the better delivery ability and higher therapeutic efficacy of ChemoRad NPs [84]. In 2013, Zheng et al. successfully synthesized PLGA–lecithin–PEG hybrid NPs, which inhibit DOX-sensitive MCF-7 cells and DOX-resistant MCF-7/ADR cells growth through doxorubicin (DOX) and indocyanine green (ICG) loaded in PLGA–lecithin–PEG nanoparticles (DINPs); these DOX/ICG-loaded lipid–polymer nanoparticles show faster DOX release, longer retention time in tumors, and improved chemo-photothermal behavior under laser irradiation [85].

### 3.4. Polymeric Nanoparticles

Polymeric nanoparticles (PMs) are particles in the size range of 10–1000 nm, formed by amphiphilic block copolymers that consist of hydrophilic and hydrophobic polymeric chains connected via covalent bonds [86]. PMs are spontaneously formed by the self-assembly of block copolymers when placed in an aqueous environment [86]. Moreover, anticancer drugs can be loaded into a polymer core or adsorbed on the surface of a polymer shell [87]. Nanocapsules are capsule systems in which the drug is confined within a cavity surrounded by a unique polymeric membrane, while nanospheres are matrix systems in which the drug is physically and uniformly dispersed in the matrix [86,88]. Biocompatibility, biodegradability, and nontoxicity are the main features of polymeric NPs. According to report from Maurya et al., the use of polymeric NPs is safe for humans [86]. The advantages of polymeric NPs as drug carriers include the fact that they can control the drug release rate, protect drugs and other biologically active molecules from environmental influences, and improve bioavailability and therapeutic index of drug [87].

When using polymeric nanoparticles as carriers of anticancer drugs, they are not usually destroyed by phagocytes in circulation, but sequestration occurs in MPS-enriched organs. If the polymeric nanoparticles are not biodegradable, the particles will accumulate in these organs, most commonly in the liver and spleen, eventually leading to toxicity and other negative side effects [89].

Hadia et al. developed a polymeric nanoparticle of chitosan-encapsulating docetaxel-cyclodextrins successfully with ionic gelation method; they figured that this DTX CDs/CS polymer nanoparticle shows considerable advantages in drug release compared to pure the drug [90]. In addition, they assessed the safety of the PM by giving oral CDs to rabbits. They found that sulfobutylether  $\beta$ -cyclodextrin (BE7- $\beta$ -CD) and other kinds of CDs remain intact and are nearly nonabsorbent in the gastrointestinal tract; CDs that enter the circulation are excreted only by the kidney [90]. They showed minimal reversible toxicity to the kidneys, liver, and lungs which depends on the dose and duration of administration [90]. Another recently studied PM is L-glutamic acid-g-p (HEMA) polymeric nanoparticle; a study in 2020 used the human bronchial epithelial cell line (16 HBE) and human monocytic cell line (THP-1) cultured in vitro to perform the cell migration test for a wound-healing study. They observed 21% percentage closure difference between control and exposure groups at 2 h; this indicates that the cell proliferation and migration of exposed cells were slower than control cells [91]. Although some studies suggested that amines in poly L-glutamic acid in nanoparticles can affect toxicity, which may induce hemolysis [92,93], they found no effect of HEMA on red blood cells from rabbit fresh blood samples [91]. The hen's egg test/chorioallantoic membrane test is the standard test in vitro study of ocular irritation for alternatives to animal testing [94], with intravenous administration of HEMA, and no hemorrhage, vascular lysis, or coagulation effects were shown, thus hinting that HEMA-based nanoparticles are a safe ocular drug-delivery system [91]. However, due to the limitations of their research methods, their experiments were not able to assess the toxicity of HEMA in vivo truly and roundly. Poly-alkyl cyanoacrylate (PACA) has good biodegradability and a high loading capacity, making it a promising drug carrier [95]. Einar et al. noted that PACA has a certain cytotoxicity which was associated with the degradation rate. PBCA, PEBCA, and POCA are the three types of PACAs. PEBCA NPs with an intermediate degradation rate were significantly less toxic than both PBCA and POCA NPs (fast and slow degradation rate). This toxic effect may be related to the aggregation and perinuclear localization of intracellular lysosomes induced by PACA [96]. In Table 2, we summarized the studies on toxicity experiments of different polymer nanoparticles. However, more extensive studies are needed to clarify the true metabolic process and toxicity of polymers in vivo. Taken together, according to the existing evidence as shown in Table 2 which summarized the studies on toxicity experiments of different polymeric nanoparticles, polymer-based nanoparticles have good biocompatibility and low toxicity; thus, they have a broad prospect for targeted drug transport.

**Table 2.** Experimental studies on toxicity of polymeric nanoparticles.

Biological System	Administration Route	Type of PMs	Mechanism of Toxicity	The Main Factors Affecting Toxicity	Reference
Rabbits	Incubation	CDs	Reversed kidney vacuolization; not toxic to heart, liver, spleen, and lungs	Dose and duration of administration	[90]
16 HBE and THP-1 cultured in vitro,	Straight way	HEMA	Slowing wound healing by affecting cell proliferation, migration, and uptake or ocular vascular occlusion	size and morphology of NPs	[91]
Fresh blood samples from rabbits,	Straight way	HEMA	No promotion of hemolysis		[91]
egg chorioallantoic membrane	intravenous	HEMA	No promotion of ocular vascular occlusion		[91]
Cell model cultured in vitro	Straight way	PACA	Lysosomal clustering and perinuclear localization	Degradation rate	[96]

### 3.4.1. Functionalization of Polymeric Nanoparticles

The polymerization modification of PMs by chemical methods is the most common method of functionalization. Some examples of shielding groups involved in chemical modification include polysaccharides, polyacrylamide, poly (vinyl alcohol), poly (N-vinyl-2-pyrrolidone), PEG, and copolymers containing PEG, such as polyoxamine, polyoxamine, polysorbitol, and PEG copolymers [97]. Of all polymers tested so far, PEG and copolymers containing PEG are the most effective and commonly used method [97]. These polymers are usually highly hydrophilic and charge neutral, and they can help shield even hydrophobic or charged particles of blood proteins [89].


Shi et al. constructed FA-PEG/PEO-PPO-PCL mixed micelles loaded with DTX to enhance the targeting specificity of DTX and improve the anticancer efficiency [98]. Palanikumar et al. designed pH-responsive hybrid ATRAM-BSA-PLGA NPs, which are composed of a cross-linked bovine serum albumin shell and encapsulated PLGA core, and the shell is functionalized by acidity triggered rational membrane (ATRAM) peptide [99]. The mixed polymeric micelles have an ideal size and low CMC value and negligible hemolytic activity, which, respectively, ensure their good accumulation in tumor tissue, high circulation stability, and good biocompatibility [100,101].

To date, PEGylation is still the benchmark for the development of functional nanocarriers in drug-delivery systems. Nevertheless, it is interesting to note that many reports indicate that PEG nanoparticles can cause unexpected immunogenic reactions, which lead to “accelerated blood clearance (ABC) phenomenon” and hypersensitivity reactions (HSRs) [102]. The specific mechanism is shown in Figure 3 below. After repeated injection of PEGylated liposomes in rats, the hepatic accumulation increase of second-dose injection hints at the important role hepatic plays in the accelerated clearance [103]. In the meanwhile, this accelerated clearing phenomenon is also observed in normal rats who receive transfusion of rat’s serum treated with PEGylated liposomes injection [104], so cellular immunity (Kupffer cells) and humoral immunity work together, resulting in this ABC phenomenon [103,104]. This drawback of PEGylation has attracted a lot of attention because it brings potential challenges to clinical work, reducing the therapeutic effect of encapsulated drugs after repeated administration [102]. After the first injection of PEGylated liposomes, they bind to B cells in the splenic marginal zone, triggering the production of anti-PEG IgM antibody in a manner independent of T cells [105]; this will enhance the uptake of PEGylated liposomes by hepatic Kupffer cells in the second dose of PEGylated liposomes injection, leading to an increase in the clearance rate [106,107]. The carrier structure may affect the ABC phenomenon. Xu et al. modified liposomes with cleavable PEG-lipid derivatives (PEG-CHEMS and PEG-CHMC), and only a slight ABC phenomenon was induced [108].

Similarly, gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle induced no ABC phenomenon, while PEGylated liposome induced a strong ABC phenomenon [109]. Maitani et al. pointed out that the micelle hydrophobic core or lipid bilayer of PEGylated liposome plays an important role on this phenomenon [109]. The drug encapsulated in the carrier seems to be an important factor that may affect the ABC phenomenon. In clinical application, repeated injection of PEGylated liposomal doxorubicin reduces its clearance; one study attributed this to the toxic activity of doxorubicin on the hepatic and splenic reticuloendothelial system [110]. Ishida et al. proved that encapsulated doxorubicin reduces the production of anti-PEG IgM by interfering with the proliferation of B cells and subsequently reducing immune response against PEGylated liposomes [111]. This could be verified in repeated injections of PEGylated liposomal topotecan in rats which induce a strong ABC phenomenon [112], because as a cell-cycle phase-specific drug, topotecan can only inhibit a fraction of B lympholeukocytes in the S phase of the cell cycle [112]. The injection of PEGylated nanocarriers can interact with the immune system and result in undesirable HSRs, also known as C-activation-related pseudoallergy (CARPA) [113]. Although the exact mechanism of PEG-induced HSRs has not been fully elucidated, there is growing evidence showing that complement activation plays a role in the process [114,115]. The complement system releases C3a and C5a, which lead to the activation of inflammatory cells, such as macrophages, basophils, and mast cells, and promote the occurrence of HSRs [114–116]. Recent research highlights the important role of anti-PEG antibodies in the PEG-induced CARPA classic pathway at least for the case of Pegfilgrastim (PEG-G-CSF) and PEGylated liposomes [117,118]. The use of other alternative chemical groups such as PDX [119], poly(amino acid)-based biodegradable polymers [120], and polycaprolactone containing sulfobetaine [121] have been proposed, but a better strategy is to minimize the immunogenicity of PEG; the use of increasingly branched PEGs (i.e., hyperbranched, star, dendritic, and bottlebrush) of lower per-branch molecular weight may diminish recognition by backbone-specific antibodies, while still maintaining the advantages of PEG [122]. Compared to the methoxy (OCH<sub>3</sub>), which is a common terminal group of polymers used in clinical applications, hydroxyl PEG-modified liposomes (PL-OH) efficiently reduced the anti-PEG IgM response in vitro [123]. Other attempts to modify terminal polymer groups include zwitterionic, ethoxy, and n-butyl ether [124,125]. Khanna et al. reported that pretreatment with mycophenolate mofetil, a B/T cell immunosuppressant, significantly improved treatment outcomes in a Phase I trial of patients with gout receiving pegloticase; this suggests that pretreatment or conjugation with an immunosuppressant may diminish the polymer immunogenicity [126]. Further research is urgently needed to improve our poor mechanistic understanding of polymer-induced immunogenicity and its associated short- and long-term health risks.

Compared with other nanomaterials, polylactide (PLA) and polylactic-co-glycolic acid (PLGA) are the most promising polymeric candidates for drug-delivery systems, as they have low toxicity and are biodegradable, exhibiting good biocompatibility [127]. By controlling the size, shape, molecular weight, and the L:G ratio, PLA and PLGA can obtain ideal pharmacokinetic characteristics [128,129]. PLA can be also assembled as a hydrophobic block with other polymers, such as PEG, to produce amphiphilic block copolymers [100]. In the drug-delivery system, the stealth property is endowed by hydrophilic corona of amphiphilic copolymer micelles, and this reduces their uptake by reticuloendothelial system; this will prolong the lifetime of a loaded drug in the blood, improving the bioavailability [130]. In one study, the graphene oxide/PLA-PEG composites constructed showed a satisfactory paclitaxel loading capacity and drug-release performance, and this complex could enter the A549 cancer lung cancer vitro cells model and exhibited good cytotoxicity [131]. PLA-based nanoparticles show special advantages on alternative routes of administration (e.g., oral, pulmonary, and mucosal), as well as prolonged gene delivery efficacy [132,133]. In an MDA-MB-435s (cancer cells) murine xenograft model, the small interfering polo-like kinase 1 (siPlk1) delivered by PEG-PLA nanoparticles showed good results, which suppressed the tumor growth significantly [134]. The application of a B6-NP-encapsulated neuropro-

protective peptide, NAPVSIPQ (NAP), in the Alzheimer's disease mouse model can produce excellent amelioration even at low doses [135]. This study shows that B6-peptide-modified NP can overcome the blood–brain barrier and has potential application in the targeted drug-delivery system for brain tumors [135]. In addition, Lv. et al. reported a novel nanocomposite of polylactide (PLA) nanofibers and tetraheptylammonium-capped Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticles; they verified this nanocomposite could effectively facilitate the interaction of daunorubicin with leukemia cells and remarkably enhance the permeation and drug uptake of anticancer agents in the cancer cells [136]. By increasingly functionalizing the PLA-based amphiphilic copolymer micelles and nanoparticles, key requirements for drug delivery, including stealthiness, controlled drug release, and targeting properties, are being met. However, new PLA-based nanoparticles that have been modified or connected with other polymers, and other nanoparticle types are emerging endlessly; their effectiveness and security in clinical are still waiting to be verified.



**Figure 3.** The mechanism of ABC phenomenon and HSRs induced by PEGylated liposomes for its immunogenicity.

### 3.4.2. Clinical Application of Polymeric Nanoparticles


PMs and their functionalization have been extensively explored for the treatment of various types of tumors because of their interaction with the well-known and well-studied tumor microenvironment. Amongst the various micellar formulations, PTX PMs have proven to have good clinical efficacy in treating advanced stages of lung cancer [137], breast cancer [138], central nervous system cancers [139], and oophoroma [140]. Zhou et al. used the solid-phase synthesis method to construct a paclitaxel long circulating nano-liposome targeting lung cancer and carried out experiments with tumor-bearing nude mice [137]. They found that this could improve the safety of paclitaxel administration and antitumor efficacy by improving the tissue distribution of paclitaxel in the body [137]. Shi et al. introduced ethoxy polyethylene glycol folic acid (FA-PEG) into the DTX-loaded micelles as an effective targeting part of the FA-PEG/PEO-PPO-PCL micelles prepared [98]. The experiments showed that it has excellent self-assembly ability in water and strong antidilution stability in circulation [98]. In addition, *in vitro* cytotoxicity results showed that FA-PEG/PEO-PPO-PCL micelles had higher cytotoxicity on FR-positive MCF-7 cells than PEO-PPO-PCL micelles [98]. Interestingly, Chen et al. reported a kind of cancer cell membrane hidden nanoparticle for the targeted delivery of doxorubicin and PD-L1 siRNA [141]. Through cell membrane stealth, biomimetic nanoparticles can be modified and functionalized through self-recognition and source-targeting capabilities, accompanied by long blood circulation and escape from immune capture, to achieve precise cancer targeted therapy [141].

### 3.5. Protein Nanoparticles

Proteins are naturally existing biomolecules that are considered to be ideal materials for nanoparticle preparation, owing to their safety, biocompatibility, and biodegradability [142]. This kind of nanoparticles from natural proteins can be metabolized by the body and easily surface modified with anticancer drug attachment and ligand binding [143]. Proteins can be divided into two types: animal proteins, such as albumin, gelatin, elastin, milk protein, and whey protein; and plant proteins, such as gliadin, soybean protein, and corn protein [144].

#### 3.5.1. Animal Proteins

Although the term “albumin” is often associated with serum albumin, it is also often used to describe a family of proteins characterized by being soluble in water [145]. In this family, serum albumin and whey protein are the most used proteins for preparing drug-delivery nanoparticles [146]. Two main members of the serum albumin group are human (HSA) and bovine serum albumin (BSA). HSA is widely used as a safe and effective carrier protein in different delivery systems due to the fact that it is a more nonimmunogenic plasma protein [146]. In Figure 4 below, we show different types of albumin-based carriers.



**Figure 4.** Different types of albumin-based carriers.

Albumin has two main binding sites, allowing for the complexation of metals, fatty acids and drugs including cisplatin, protein and peptide drugs [147]. The presence of these sites makes it possible to functionalize the specific delivery of a therapeutic moiety [148]. Albumin-based nanoparticles can be modified or loaded with targeting ligands on surface to change body distribution and improve their cellular uptake; this could avoid undesirable drug toxicity to some extent and improve the drug-targeting ability [148,149]. Wu et al. developed albumin copolymer micelles for delivery of doxorubicin; during the preparation, the hydrophobic interaction between polypeptide scaffolds is used to load doxorubicin; and compared with free DOX, this carrier shows higher drug cytotoxicity and higher PH dependent stability [150]. In addition to drugs, proteins can be also delivered by the BSA-based micelles to their target site. Jiang et al. prepared BSA-based polyionic complex micelles for Spry1 delivery. These micelles showed improved cytotoxicity on MCF7, which belongs to breast cancer cell lines, and exhibited high anticancer efficacy by inhibiting the growth of three dimensional MCF-7 multicellular tumor spheroids [151]. Moreover, in the past few years, various albumin-based nanoconjugates, including albumin–polymer conjugate, albumin–drug conjugate, and albumin–metal conjugate, have also been investi-

gated. Cysteine (Cys) and lysine (Lys) residues of albumin are the most explored binding sites for preparing covalently conjugated albumin nanoconjugates; meanwhile, the non-covalent interaction between albumin and conjugation moiety is because of hydrophobic and electrostatic interactions, which also act as a driving force in the formation of albumin conjugates [152]. Because albumin has a long half-life in the human body, an albumin–drug conjugate prolonged the drug circulation *in vivo*, which also can ameliorate and overcome the multidrug resistance of anticancer drugs [153]. Several drugs, including DOX, cisplatin, docetaxel, etc., were used to prepare albumin–drug conjugates. Docetaxel–albumin conjugates were developed and verified by Esmaeili et al.; they possessed enhanced solubility and tumor targeting ability [154]. Similarly, the conjugate of SN38-HSA exhibited better solubility and stability [153]. Although the albumin-based nanodrug-delivery system has great advantages, the inherent disadvantages of albumin are its limited application, including intrinsic target groups lacking protein hydrolysis stability; and its limited and low applicability to hydrophilic and electrophilic drugs [155,156]. However, by conjugating albumin with another polymer, these drawbacks can be overcome. Compared to the polymer–platinum conjugate without albumin coating, the albumin-coated polymer–platinum conjugate can significantly increase the uptake rate of ovarian cancer cells and enhance their cell toxicity [157]. Moreover, as previously mentioned, Liang et al. suggested NDs labeled by PEGylated denatured bovine serum albumin (BSA) and tumor vasculature targeting tripeptides RGD, which is dcBSA-PEG-NDs, showed high efficiency in selectively targeting tumor sites in U-87 MG bearing mice through BBB [58]. In another study, Liu et al. prepared DOX-encapsulated cetuximab-functionalized BSA–PCL nanovesicle as a tumor-targeted nanocarrier, and they observed enhanced antitumor activity [158]. Tang et al. developed vitamin E (VE)–albumin core–shell nanoparticles for paclitaxel (PTX) delivery to improve the chemotherapy effect in MDR breast cancer models. Compared with NPs without VE (PTX NPs), PTX VE NPs significantly increased the cell uptake of PTX, showing stronger cytotoxicity and higher anticancer efficacy [159]. Shen et al. prepared the delivery system of hyaluronic acid and human serum albumin modified erlotinib nanoparticles (ERT-HSA-HA NPs) by using a precipitation method. An *in vivo* study found that the particles showed excellent anti proliferation effect on A549 cells. In terms of antitumor activity *in vivo*, ERT-HSA-HA-NP-treated mice showed significantly inhibited tumor growth and no recurrence after 30 days of treatment [160]. In conclusion, albumin-based nanocarriers have the advantages of being relatively safe and easy to prepare, the capability to deliver different types of molecules, and site-specific targeting by surface modification. These properties make albumin the most widely used protein for drug-delivery systems' preparation.

### 3.5.2. Plant Proteins

Compared with animal protein, plant protein has better biocompatibility and less immunogenicity [161]. Lee et al. developed chondroitin sulfate hybrid zein nanoparticles for the targeted delivery of docetaxel. Compared with free docetaxel, these NPs have improved pharmacokinetic properties and significantly enhanced antitumor efficacy, and the systemic toxicity caused can be ignored [162]. Gulfam et al. used an electrospray deposition system to synthesize gliadin and gliadin gelatin composite nanoparticles to control the delivery of anticancer drugs (such as cyclophosphamide) and regulate their release rate, and they proved that cyclophosphamide-loaded 7% gliadin nanoparticles can make breast cancer cells engage in apoptosis 24 h later [163]. More and more researchers are paying attention to protein nanoparticles; there are also many articles reporting the research progress of various protein nanoparticles. However, researchers still need to consider how to make more protein nanoparticles into clinical applications, not just research. In addition, the safety and effectiveness of protein nanoparticles as anticancer drug carriers need to be further determined by *in vivo* research.

#### 4. Conclusions

In this review, we highlighted the recent advances in the development and application of nanoparticles in cancer treatment and summarized the advantages and disadvantages of the main nanoparticles in Table 3. Nanoparticles can be passively targeted toward tumor tissues due to their special size. However, with the continuous development of nano-engineering, various surface-modified nanomolecules can be more efficient and specifically targeted toward tumor cells. For example, many nanoparticles modified by specific ligands and monoclonal antibodies have been used in clinical trials and clinical drug targeting transportation systems. The accumulation of gold nanoparticles in tumor cells will induce tumor-cell-proliferation stagnation and apoptosis, but at the same time, it will also induce autophagy to improve the anti-external damage ability of tumor cells. Embedding anti-autophagic drugs in gold nanoparticles may be a solution. The photothermal effects of gold and carbon nanoparticles provide new possibilities for antitumor therapy based on surgery, radiotherapy, and chemotherapy, but their safety and availability need to be further studied and improved. Polymer nanoparticles and protein-based nanoparticles show outstanding biocompatibility and low toxicity. Liposome nanoparticles have been widely used in the clinic. Current studies and clinical trials focus on the modification of liposomes and the embedding of polymers to improve their effects. Liposomes loaded with new chemotherapy drugs and special RNA show different possibilities in the treatment of different tumors. The increasing surface-modified particles have improved their antitumor specificity to some extent in *in vitro* experiments; this also increases its instability and the risk of biological toxicity after metabolism *in vivo*. With the emerging and rapid development in nanomedicine, it will still be a huge challenge for us to balance biocompatibility and toxicity in the future.

**Table 3.** Major nanoparticles involved in this review and their features.

Types of Nanomaterials	Main Features	References
Au NPs	Stability, low toxicity. Gene therapy, protooncogenes silencing. Ideal photothermal conversion materials.	[31] [35]
Au-Ag NPs	Photothermal therapy. Inducing cell-cycle arrest and cell apoptosis.	[41] [44,48,49]
Carbon nanomaterials	Rich forms including fullerenes, nanotubes and nanodiamonds. Low toxicity, high biocompatibility. Specific recognition of tumor tissue during treatment and surgery. Photothermal therapy.	[56] [64,66,67] [70]
Lipid-based nanoparticles	Widely used, high biocompatibility, biodegradability	[72]
Polymeric nanoparticle	Safe, low toxicity.	[86]
PEG-based nanoparticles	Drug half lifetime prolonged. Immunogenicity inducing ABC phenomenon	[102–104]
PLA-based nanoparticles	Biodegradability, low toxicity.	[127]
Albumin-based nanoparticles	Drug half-lifetime prolonged. Development of various conjugates	[153] [152]

**Author Contributions:** Conceptualization, J.C. (Jiawei Chen) and Y.W.; validation; data curation, J.C. (Juan Chen); writing—original draft preparation, D.Z. and Q.T.; writing—review and editing, Y.W.; supervision, Y.W.; funding acquisition, Y.W. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Futian Healthcare Research Project (No. FTWS2020079).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available upon request from the corresponding author.

**Acknowledgments:** We thank Qingnan Huang, Yong Chen, Kai Zeng, Mingliang Huang, and Weiqin Yang for reviewing this manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. *CA Cancer J. Clin.* **2022**, *72*, 7–33. [[CrossRef](#)] [[PubMed](#)]
2. Zraik, I.M.; Hess-Busch, Y. Management of chemotherapy side effects and their long-term sequelae. *Urol. A* **2021**, *60*, 862–871. [[CrossRef](#)] [[PubMed](#)]
3. Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. *Nat. Rev. Cancer* **2017**, *17*, 20–37. [[CrossRef](#)] [[PubMed](#)]
4. Alasvand, N.; Urbanska, A.M.; Rahmati, M.; Saeidifar, M.; Gungor-Ozkerim, P.S.; Sefat, F.; Rajadas, J.; Mozafari, M. *Therapeutic Nanoparticles for Targeted Delivery of Anticancer Drugs*; Elsevier: Amsterdam, The Netherlands, 2017; pp. 245–259.
5. Wu, J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. *J. Pers. Med.* **2021**, *11*, 771. [[CrossRef](#)] [[PubMed](#)]
6. Sahay, G.; Alakhova, D.Y.; Kabanov, A.V. Endocytosis of nanomedicines. *J. Control. Release* **2010**, *145*, 182–195. [[CrossRef](#)]
7. Wang, S.; Zheng, Y.; Yang, F.; Zhu, L.; Zhu, X.Q.; Wang, Z.F.; Wu, X.L.; Zhou, C.H.; Yan, J.Y.; Hu, B.Y.; et al. The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives. *Signal Transduct. Target Ther.* **2021**, *6*, 249. [[CrossRef](#)]
8. Sasaki, T.; Hiroki, K.; Yamashita, Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. *Biomed. Res. Int.* **2013**, *2013*, 546318. [[CrossRef](#)]
9. Friedlaender, A.; Subbiah, V.; Russo, A.; Banna, G.L.; Malapelle, U.; Rolfo, C.; Addeo, A. EGFR and HER2 exon 20 insertions in solid tumours: From biology to treatment. *Nat. Rev. Clin. Oncol.* **2022**, *19*, 51–69. [[CrossRef](#)]
10. Iqbal, N.; Iqbal, N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Mol. Biol. Int.* **2014**, *2014*, 852748. [[CrossRef](#)]
11. Goel, H.L.; Mercurio, A.M. VEGF targets the tumour cell. *Nat. Rev. Cancer* **2013**, *13*, 871–882. [[CrossRef](#)]
12. Yang, J.; Yan, J.; Liu, B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity. *Front. Immunol.* **2018**, *9*, 978. [[CrossRef](#)] [[PubMed](#)]
13. Xie, Y.; Su, N.; Yang, J.; Tan, Q.; Huang, S.; Jin, M.; Ni, Z.; Zhang, B.; Zhang, D.; Luo, F.; et al. FGF/FGFR signaling in health and disease. *Signal Transduct. Target Ther.* **2020**, *5*, 181. [[CrossRef](#)]
14. Maerz, W.J.; Baselga, J.; Reuter, V.E.; Mellado, B.; Myers, M.L.; Bosl, G.J.; Spinella, M.J.; Dmitrovsky, E. FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. *Oncogene* **1998**, *17*, 761–767. [[CrossRef](#)] [[PubMed](#)]
15. Giulianelli, S.; Riggio, M.; Guillardoy, T.; Perez Pinero, C.; Gorostiaga, M.A.; Sequeira, G.; Pataccini, G.; Abascal, M.F.; Toledo, M.F.; Jacobsen, B.M.; et al. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERalpha and PRBDelta4 isoform to MYC regulatory sequences. *Int. J. Cancer* **2019**, *145*, 1874–1888. [[PubMed](#)]
16. Martinez-Torrecuadrada, J.; Cifuentes, G.; Lopez-Serra, P.; Saenz, P.; Martinez, A.; Casal, J.I. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. *Clin. Cancer Res.* **2005**, *11*, 6280–6290. [[CrossRef](#)]
17. Markham, A. Erdafitinib: First Global Approval. *Drugs* **2019**, *79*, 1017–1021. [[CrossRef](#)]
18. Hoy, S.M. Pemigatinib: First Approval. *Drugs* **2020**, *80*, 923–929. [[CrossRef](#)]
19. Palumbo, R.; Sottotetti, F.; Bernardo, A. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: Which benefit for which patients? *Ther. Adv. Med. Oncol.* **2016**, *8*, 209–229. [[CrossRef](#)]
20. Weitman, S.D.; Lark, R.H.; Coney, L.R.; Fort, D.W.; Frasca, V.; Zurawski, V.R., Jr.; Kamen, B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. *Cancer Res.* **1992**, *52*, 3396–3401.
21. Campbell, I.G.; Jones, T.A.; Foulkes, W.D.; Trowsdale, J. Folate-binding protein is a marker for ovarian cancer. *Cancer Res.* **1991**, *51*, 5329–5338.
22. Hartmann, L.C.; Keeney, G.L.; Lingle, W.L.; Christianson, T.J.; Varghese, B.; Hillman, D.; Oberg, A.L.; Low, P.S. Folate receptor overexpression is associated with poor outcome in breast cancer. *Int. J. Cancer* **2007**, *121*, 938–942. [[CrossRef](#)] [[PubMed](#)]
23. Allard, J.E.; Risinger, J.I.; Morrison, C.; Young, G.; Rose, G.S.; Fowler, J.; Berchuck, A.; Maxwell, G.L. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. *Gynecol. Oncol.* **2007**, *107*, 52–57. [[CrossRef](#)] [[PubMed](#)]
24. Chan, K.T.; Choi, M.Y.; Lai, K.K.; Tan, W.; Tung, L.N.; Lam, H.Y.; Tong, D.K.; Lee, N.P.; Law, S. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. *Oncol. Rep.* **2014**, *31*, 1296–1304. [[CrossRef](#)] [[PubMed](#)]

25. Zheng, C.; Ma, C.; Bai, E.; Yang, K.; Xu, R. Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma. *Int. J. Clin. Exp. Med.* **2015**, *8*, 1658–1668. [[PubMed](#)]
26. Sharbeen, G.; McCarroll, J.A.; Akerman, A.; Kopecky, C.; Youkhana, J.; Kokkinos, J.; Holst, J.; Boyer, C.; Erkan, M.; Goldstein, D.; et al. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. *Cancer Res.* **2021**, *81*, 3461–3479. [[CrossRef](#)] [[PubMed](#)]
27. Juan, A.; Cimas, F.J.; Bravo, I.; Pandiella, A.; Ocana, A.; Alonso-Moreno, C. Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. *Int. J. Mol. Sci.* **2020**, *21*, 6018. [[CrossRef](#)]
28. Ren, Y.; Wang, R.R.; Gao, L.Z.; Li, K.; Zhou, X.; Guo, H.; Liu, C.Y.; Han, D.L.; Tian, J.G.; Ye, Q.; et al. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy. *J. Control. Release* **2016**, *228*, 74–86. [[CrossRef](#)]
29. Kim, D.; Jeong, Y.Y.; Jon, S. A Drug-Loaded Aptamer-Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer. *ACS Nano* **2010**, *4*, 3689–3696. [[CrossRef](#)]
30. Hara, D.; Tao, W.; Totiger, T.M.; Pourmand, A.; Dogan, N.; Ford, J.C.; Shi, J.; Pollack, A. Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA). *Int. J. Radiat. Oncol. Biol. Phys.* **2021**, *111*, 220–232. [[CrossRef](#)]
31. Kanu, G.A.; Parambath, J.B.M.; Abu Odeh, R.O.; Mohamed, A.A. Gold Nanoparticle-Mediated Gene Therapy. *Cancers* **2022**, *14*, 5366. [[CrossRef](#)]
32. Conde, J.; Larginho, M.; Cordeiro, A.; Raposo, L.R.; Costa, P.M.; Santos, S.; Diniz, M.S.; Fernandes, A.R.; Baptista, P.V. Gold-nanobeacons for gene therapy: Evaluation of genotoxicity, cell toxicity and proteome profiling analysis. *Nanotoxicology* **2014**, *8*, 521–532. [[CrossRef](#)] [[PubMed](#)]
33. Hameed, M.; Panicker, S.; Abdallah, S.H.; Khan, A.A.; Han, C.; Chehimi, M.M.; Mohamed, A.A. Protein-Coated Aryl Modified Gold Nanoparticles for Cellular Uptake Study by Osteosarcoma Cancer Cells. *Langmuir* **2020**, *36*, 11765–11775. [[CrossRef](#)] [[PubMed](#)]
34. Wu, Y.; Ali, M.R.K.; Chen, K.; Fang, N.; El-Sayed, M.A. Gold nanoparticles in biological optical imaging. *Nano Today* **2019**, *24*, 120–140. [[CrossRef](#)]
35. Ungureanu, C.; Kroes, R.; Petersen, W.; Groothuis, T.A.; Ungureanu, F.; Janssen, H.; van Leeuwen, F.W.; Kooyman, R.P.; Manohar, S.; van Leeuwen, T.G. Light interactions with gold nanorods and cells: Implications for photothermal nanotherapeutics. *Nano Lett.* **2011**, *11*, 1887–1894. [[CrossRef](#)]
36. Zhao, L.; Zhang, X.; Wang, X.; Guan, X.; Zhang, W.; Ma, J. Recent advances in selective photothermal therapy of tumor. *J. Nanobiotechnol.* **2021**, *19*, 335. [[CrossRef](#)]
37. Luo, D.; Carter, K.A.; Miranda, D.; Lovell, J.F. Chemophototherapy: An Emerging Treatment Option for Solid Tumors. *Adv. Sci.* **2017**, *4*, 1600106. [[CrossRef](#)]
38. Hu, J.J.; Cheng, Y.J.; Zhang, X.Z. Recent advances in nanomaterials for enhanced photothermal therapy of tumors. *Nanoscale* **2018**, *10*, 22657–22672. [[CrossRef](#)]
39. Li, J.; Wang, W.; Zhao, L.; Rong, L.; Lan, S.; Sun, H.; Zhang, H.; Yang, B. Hydroquinone-assisted synthesis of branched au-ag nanoparticles with polydopamine coating as highly efficient photothermal agents. *ACS Appl. Mater. Interfaces* **2015**, *7*, 11613–11623. [[CrossRef](#)]
40. Lu, J.; Cai, L.; Dai, Y.; Liu, Y.; Zuo, F.; Ni, C.; Shi, M.; Li, J. Polydopamine-Based Nanoparticles for Photothermal Therapy/Chemotherapy and their Synergistic Therapy with Autophagy Inhibitor to Promote Antitumor Treatment. *Chem. Rec.* **2021**, *21*, 781–796. [[CrossRef](#)]
41. Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. *Nat. Rev. Cancer* **2017**, *17*, 528–542. [[CrossRef](#)]
42. Hao, M.; Kong, C.; Jiang, C.; Hou, R.; Zhao, X.; Li, J.; Wang, Y.; Gao, Y.; Zhang, H.; Yang, B.; et al. Polydopamine-coated Au-Ag nanoparticle-guided photothermal colorectal cancer therapy through multiple cell death pathways. *Acta Biomater.* **2019**, *83*, 414–424. [[CrossRef](#)] [[PubMed](#)]
43. Wang, Y.; Zhao, H.; Wang, D.; Hao, M.; Kong, C.; Zhao, X.; Gao, Y.; Li, J.; Liu, B.; Yang, B.; et al. Inhibition of Autophagy Promoted Apoptosis and Suppressed Growth of Hepatocellular Carcinoma Upon Photothermal Exposure. *J. Biomed. Nanotechnol.* **2019**, *15*, 813–821. [[CrossRef](#)] [[PubMed](#)]
44. Zhao, X.; Qi, T.; Kong, C.; Hao, M.; Wang, Y.; Li, J.; Liu, B.; Gao, Y.; Jiang, J. Photothermal exposure of polydopamine-coated branched Au-Ag nanoparticles induces cell cycle arrest, apoptosis, and autophagy in human bladder cancer cells. *Int. J. Nanomed.* **2018**, *13*, 6413–6428. [[CrossRef](#)] [[PubMed](#)]
45. Pagano, M.; Pepperkok, R.; Verde, F.; Ansorge, W.; Draetta, G. Cyclin A is required at two points in the human cell cycle. *EMBO J.* **1992**, *11*, 961–971. [[CrossRef](#)]
46. Vermeulen, K.; Van Bockstaele, D.R.; Berneman, Z.N. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. *Cell Prolif.* **2003**, *36*, 131–149. [[CrossRef](#)] [[PubMed](#)]
47. Sivakumar, D.; Sivaraman, T. A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens. *Protein Pept. Lett.* **2016**, *23*, 932–941. [[CrossRef](#)] [[PubMed](#)]
48. Wang, W.; Liu, J.; Feng, W.; Du, S.; Ge, R.; Li, J.; Liu, Y.; Sun, H.; Zhang, D.; Zhang, H.; et al. Targeting mitochondria with Au-Ag@Polydopamine nanoparticles for papillary thyroid cancer therapy. *Biomater. Sci.* **2019**, *7*, 1052–1063. [[CrossRef](#)] [[PubMed](#)]

49. Park, S.; Lee, W.J.; Park, S.; Choi, D.; Kim, S.; Park, N. Reversibly pH-responsive gold nanoparticles and their applications for photothermal cancer therapy. *Sci. Rep.* **2019**, *9*, 20180. [[CrossRef](#)]
50. Boedtker, E.; Pedersen, S.F. The Acidic Tumor Microenvironment as a Driver of Cancer. *Annu. Rev. Physiol.* **2020**, *82*, 103–126. [[CrossRef](#)]
51. Diez-Pascual, A.M. Carbon-Based Nanomaterials. *Int. J. Mol. Sci.* **2021**, *22*, 7726. [[CrossRef](#)]
52. Auria-Soro, C.; Nesma, T.; Juanes-Velasco, P.; Landeira-Vinuela, A.; Fidalgo-Gomez, H.; Acebes-Fernandez, V.; Gongora, R.; Almendral Parra, M.J.; Manzano-Roman, R.; Fuentes, M. Interactions of Nanoparticles and Biosystems: Microenvironment of Nanoparticles and Biomolecules in Nanomedicine. *Nanomaterials* **2019**, *9*, 1365. [[CrossRef](#)]
53. Garriga, R.; Herrero-Contiente, T.; Palos, M.; Cebolla, V.L.; Osada, J.; Munoz, E.; Rodriguez-Yoldi, M.J. Toxicity of Carbon Nanomaterials and Their Potential Application as Drug Delivery Systems: In Vitro Studies in Caco-2 and MCF-7 Cell Lines. *Nanomaterials* **2020**, *10*, 1617. [[CrossRef](#)] [[PubMed](#)]
54. Kundranda, M.N.; Niu, J. Albumin-bound paclitaxel in solid tumors: Clinical development and future directions. *Drug Des. Dev. Ther.* **2015**, *9*, 3767–3777. [[CrossRef](#)] [[PubMed](#)]
55. Shao, W.; Paul, A.; Rodes, L.; Prakash, S. A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel. *Cell Biochem. Biophys.* **2015**, *71*, 1405–1414. [[CrossRef](#)] [[PubMed](#)]
56. Gupta, C.; Prakash, D.; Gupta, S. Cancer treatment with nano-diamonds. *Front. Biosci.* **2017**, *9*, 62–70. [[CrossRef](#)]
57. Obermeier, B.; Daneman, R.; Ransohoff, R.M. Development, maintenance and disruption of the blood-brain barrier. *Nat. Med.* **2013**, *19*, 1584–1596. [[CrossRef](#)]
58. Leung, H.M.; Lau, C.H.; Ho, J.W.; Chan, M.S.; Chang, T.J.H.; Law, L.H.; Wang, F.; Tam, D.Y.; Liu, L.S.; Chan, K.W.Y.; et al. Targeted brain tumor imaging by using discrete biopolymer-coated nanodiamonds across the blood-brain barrier. *Nanoscale* **2021**, *13*, 3184–3193. [[CrossRef](#)]
59. Moscariello, P.; Raabe, M.; Liu, W.; Bernhardt, S.; Qi, H.; Kaiser, U.; Wu, Y.; Weil, T.; Luhmann, H.J.; Hedrich, J. Unraveling In Vivo Brain Transport of Protein-Coated Fluorescent Nanodiamonds. *Small* **2019**, *15*, e1902992. [[CrossRef](#)]
60. Bi, Y.; Zhang, Y.; Cui, C.; Ren, L.; Jiang, X. Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7. *Int. J. Nanomed.* **2016**, *11*, 5771–5787. [[CrossRef](#)] [[PubMed](#)]
61. Davies, L.; Welch, H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. *JAMA* **2006**, *295*, 2164–2167. [[CrossRef](#)]
62. Lim, H.; Devesa, S.S.; Sosa, J.A.; Check, D.; Kitahara, C.M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. *JAMA* **2017**, *317*, 1338–1348. [[CrossRef](#)]
63. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **2016**, *26*, 1–133. [[CrossRef](#)] [[PubMed](#)]
64. Pavlov, A.V. Regeneration of the parathyroid glands following mechanical trauma. *Arkh. Anat. Gistol. Embriol.* **1983**, *84*, 61–67. [[PubMed](#)]
65. Liu, J.; Xu, C.; Wang, R.; Han, P.; Zhao, Q.; Li, H.; Bai, Y.; Liu, L.; Zhang, S.; Yao, X. Do carbon nanoparticles really improve thyroid cancer surgery? A retrospective analysis of real-world data. *World J. Surg. Oncol.* **2020**, *18*, 84. [[CrossRef](#)] [[PubMed](#)]
66. Liang, S.; Wang, Z.; Chen, J.; Yang, X.; Liang, X.; Sun, X.; Li, X.; Zhou, R.; Li, Y.; Wang, J. Carbon nanoparticles combined with indocyanine green for sentinel lymph node detection in endometrial carcinoma. *J. Surg. Oncol.* **2021**, *124*, 411–419. [[CrossRef](#)]
67. Feng, Y.; Yang, K.; Sun, H.H.; Liu, Y.P.; Zhang, D.; Zhao, Y.; Shi, W.; Lu, G.F.; Zhang, Z.Y.; Jia, A.; et al. Value of preoperative gastroscopic carbon nanoparticles labeling in patients undergoing laparoscopic radical gastric cancer surgery. *Surg. Oncol.* **2021**, *38*, 101628. [[CrossRef](#)]
68. Zhang, M.; Luo, Y.; Zhang, Y.; Tang, J. Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma: A Prospective Study. *Thyroid* **2016**, *26*, 1581–1587. [[CrossRef](#)]
69. Min, Y.; Wang, X.; Chen, H.; Chen, J.; Xiang, K.; Yin, G. Thermal Ablation for Papillary Thyroid Microcarcinoma: How Far We Have Come? *Cancer Manag. Res.* **2020**, *12*, 13369–13379. [[CrossRef](#)]
70. Huang, Y.; Zeng, G.; Xin, Q.; Yang, J.; Zeng, C.; Tang, K.; Yang, S.T.; Tang, X. Carbon nanoparticles suspension injection for photothermal therapy of xenografted human thyroid carcinoma in vivo. *MedComm* **2020**, *1*, 202–210. [[CrossRef](#)]
71. Haider, M.; Abidin, S.M.; Kamal, L.; Orive, G. Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. *Pharmaceutics* **2020**, *12*, 288. [[CrossRef](#)]
72. Chaudhuri, A.; Kumar, D.N.; Shaik, R.A.; Eid, B.G.; Abdel-Naim, A.B.; Md, S.; Ahmad, A.; Agrawal, A.K. Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy. *Int. J. Mol. Sci.* **2022**, *23*, 10068. [[CrossRef](#)]
73. Maeki, M.; Kimura, N.; Sato, Y.; Harashima, H.; Tokeshi, M. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. *Adv. Drug Deliv. Rev.* **2018**, *128*, 84–100. [[CrossRef](#)] [[PubMed](#)]
74. Arias, J.L. Liposomes in drug delivery: A patent review (2007–present). *Expert Opin. Ther. Pat.* **2013**, *23*, 1399–1414. [[CrossRef](#)] [[PubMed](#)]
75. Alavi, M.; Hamidi, M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. *Drug Metab. Pers. Ther.* **2019**, *34*, 2018003. [[CrossRef](#)] [[PubMed](#)]

76. Li, Y.; Cong, H.; Wang, S.; Yu, B.; Shen, Y. Liposomes modified with bio-substances for cancer treatment. *Biomater. Sci.* **2020**, *8*, 6442–6468. [[CrossRef](#)]
77. Li, M.; Du, C.; Guo, N.; Teng, Y.; Meng, X.; Sun, H.; Li, S.; Yu, P.; Galons, H. Composition design and medical application of liposomes. *Eur. J. Med. Chem.* **2019**, *164*, 640–653. [[CrossRef](#)]
78. Barenholz, Y. Doxil (R)—The first FDA-approved nano-drug: Lessons learned. *J. Control. Release* **2012**, *160*, 117–134. [[CrossRef](#)]
79. Liang, Y.; Duan, L.; Lu, J.; Xia, J. Engineering exosomes for targeted drug delivery. *Theranostics* **2021**, *11*, 3183–3195. [[CrossRef](#)]
80. Ohno, S.; Drummen, G.P.C.; Kuroda, M. Focus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic Systems. *Int. J. Mol. Sci.* **2016**, *17*, 172. [[CrossRef](#)]
81. Pascucci, L.; Cocce, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Vigano, L.; Locatelli, A.; Sisto, F.; Doglia, S.M.; et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. *J. Control. Release* **2014**, *192*, 262–270. [[CrossRef](#)]
82. Tian, Y.H.; Li, S.P.; Song, J.; Ji, T.J.; Zhu, M.T.; Anderson, G.J.; Wei, J.Y.; Nie, G.J. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. *Biomaterials* **2014**, *35*, 2383–2390. [[CrossRef](#)] [[PubMed](#)]
83. Mukherjee, A.; Waters, A.K.; Kalyan, P.; Achrol, A.S.; Kesari, S.; Yenugonda, V.M. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives. *Int. J. Nanomed.* **2019**, *14*, 1937–1952. [[CrossRef](#)] [[PubMed](#)]
84. Wang, A.Z.; Yuet, K.; Zhang, L.F.; Gu, F.X.; Huynh-Le, M.; Radovic-Moreno, A.F.; Kantoff, P.W.; Bander, N.H.; Langer, R.; Farokhzad, O.C. ChemoRad nanoparticles: A novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. *Nanomedicine* **2010**, *5*, 361–368. [[CrossRef](#)] [[PubMed](#)]
85. Zheng, M.B.; Yue, C.X.; Ma, Y.F.; Gong, P.; Zhao, P.F.; Zheng, C.F.; Sheng, Z.H.; Zhang, P.F.; Wang, Z.H.; Cai, L.T. Single-Step Assembly of DOX/ICG Loaded Lipid-Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination Therapy. *ACS Nano* **2013**, *7*, 2056–2067. [[CrossRef](#)] [[PubMed](#)]
86. Zielinska, A.; Carreiro, F.; Oliveira, A.M.; Neves, A.; Pires, B.; Venkatesh, D.N.; Durazzo, A.; Lucarini, M.; Eder, P.; Silva, A.M.; et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. *Molecules* **2020**, *25*, 3731. [[CrossRef](#)]
87. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. *J. Control. Release* **2001**, *70*, 1–20. [[CrossRef](#)]
88. Erdoglar, N.; Akkin, S.; Bilensoy, E. Nanocapsules for Drug Delivery: An Updated Review of the Last Decade. *Recent Pat. Drug. Deliv. Formul.* **2018**, *12*, 252–266. [[CrossRef](#)]
89. Owens, D.E.; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *Int. J. Pharm.* **2006**, *307*, 93–102. [[CrossRef](#)]
90. Sadaquat, H.; Akhtar, M.; Nazir, M.; Ahmad, R.; Alvi, Z.; Akhtar, N. Biodegradable and biocompatible polymeric nanoparticles for enhanced solubility and safe oral delivery of docetaxel: In vivo toxicity evaluation. *Int. J. Pharm.* **2021**, *598*, 120363. [[CrossRef](#)]
91. Bakan, B.; Gulcernal, S.; Akgol, S.; Hoet, P.H.M.; Karabay Yavasoglu, N.U. Synthesis, characterization and toxicity assessment of a new polymeric nanoparticle, l-glutamic acid-g-p(HEMA). *Chem. Biol. Interact.* **2020**, *315*, 108870. [[CrossRef](#)]
92. Fischer, D.; Li, Y.; Ahlemeyer, B.; Kriegelstein, J.; Kissel, T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. *Biomaterials* **2003**, *24*, 1121–1131. [[CrossRef](#)] [[PubMed](#)]
93. Lu, C.; Li, X.; Xia, W.; Lu, S.; Luo, H.; Ye, D.; Zhang, Y.; Liu, D. Poly(epsilon-benzyloxycarbonyl-L-lysine)-grafted branched polyethylenimine as efficient nanocarriers for indomethacin with enhanced oral bioavailability and anti-inflammatory efficacy. *Acta Biomater.* **2017**, *49*, 434–443. [[CrossRef](#)]
94. De Araujo Lowndes Viera, L.M.; Silva, R.S.; da Silva, C.C.; Presgrave, O.A.F.; Boas, M. Comparison of the different protocols of the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) by evaluating the eye irritation potential of surfactants. *Toxicol. In Vitro* **2022**, *78*, 105255. [[CrossRef](#)] [[PubMed](#)]
95. Vauthier, C.; Dubernet, C.; Fattal, E.; Pinto-Alphandary, H.; Couvreur, P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. *Adv. Drug Deliv. Rev.* **2003**, *55*, 519–548. [[CrossRef](#)] [[PubMed](#)]
96. Sulheim, E.; Iversen, T.G.; To Nakstad, V.; Klinkenberg, G.; Sletta, H.; Schmid, R.; Hatletveit, A.R.; Wagbo, A.M.; Sundan, A.; Skotland, T.; et al. Cytotoxicity of Poly(Alkyl Cyanoacrylate) Nanoparticles. *Int. J. Mol. Sci.* **2017**, *18*, 2454. [[CrossRef](#)] [[PubMed](#)]
97. Abd Allah, N.H.; Abouelmagd, S.A. Surface functionalization of polymeric nanoparticles for tumor drug delivery: Approaches and challenges. *Expert Opin. Drug. Deliv.* **2017**, *14*, 201–214. [[CrossRef](#)] [[PubMed](#)]
98. Shi, C.H.; Zhang, Z.Q.; Wang, F.; Luan, Y.X. Active-targeting docetaxel-loaded mixed micelles for enhancing antitumor efficacy. *J. Mol. Liq.* **2018**, *264*, 172–178. [[CrossRef](#)]
99. Palanikumar, L.; Al-Hosani, S.; Kalmouni, M.; Nguyen, V.P.; Ali, L.; Pasricha, R.; Barrera, F.N.; Magzoub, M. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. *Commun. Biol.* **2020**, *3*, 95. [[CrossRef](#)]
100. Cagel, M.; Tesan, F.C.; Bernabeu, E.; Salgueiro, M.J.; Zubillaga, M.B.; Moreton, M.A.; Chiappetta, D.A. Polymeric mixed micelles as nanomedicines: Achievements and perspectives. *Eur. J. Pharm. Biopharm.* **2017**, *113*, 211–228. [[CrossRef](#)]
101. Luo, Y.; Yin, X.; Yin, X.; Chen, A.; Zhao, L.; Zhang, G.; Liao, W.; Huang, X.; Li, J.; Zhang, C.Y. Dual pH/Redox-Responsive Mixed Polymeric Micelles for Anticancer Drug Delivery and Controlled Release. *Pharmaceutics* **2019**, *11*, 176. [[CrossRef](#)]
102. Saadati, R.; Dadashzadeh, S.; Abbasian, Z.; Soleimanjahi, H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: Effects of polymer dose, PEG coating, and encapsulated anticancer drug. *Pharm. Res.* **2013**, *30*, 985–995. [[CrossRef](#)] [[PubMed](#)]

103. Ishida, T.; Maeda, R.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. *J. Control. Release* **2003**, *88*, 35–42. [[CrossRef](#)] [[PubMed](#)]
104. Ishida, T.; Masuda, K.; Ichikawa, T.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated clearance of a second injection of PEGylated liposomes in mice. *Int. J. Pharm.* **2003**, *255*, 167–174. [[CrossRef](#)] [[PubMed](#)]
105. Ishida, T.; Wang, X.; Shimizu, T.; Nawata, K.; Kiwada, H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. *J. Control. Release* **2007**, *122*, 349–355. [[CrossRef](#)]
106. Wang, X.; Ishida, T.; Kiwada, H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. *J. Control. Release* **2007**, *119*, 236–244. [[CrossRef](#)] [[PubMed](#)]
107. Emam, S.E.; Elsadek, N.E.; Abu Lila, A.S.; Takata, H.; Kawaguchi, Y.; Shimizu, T.; Ando, H.; Ishima, Y.; Ishida, T. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. *J. Control. Release* **2021**, *334*, 327–334. [[CrossRef](#)]
108. Xu, H.; Wang, K.Q.; Deng, Y.H.; Chen, D.W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. *Biomaterials* **2010**, *31*, 4757–4763. [[CrossRef](#)]
109. Ma, H.; Shiraiishi, K.; Minowa, T.; Kawano, K.; Yokoyama, M.; Hattori, Y.; Maitani, Y. Accelerated blood clearance was not induced for a gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice. *Pharm. Res.* **2010**, *27*, 296–302. [[CrossRef](#)]
110. Gabizon, A.; Isacson, R.; Rosengarten, O.; Tzemach, D.; Shmeeda, H.; Sapir, R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. *Cancer Chemother. Pharmacol.* **2008**, *61*, 695–702. [[CrossRef](#)]
111. Ishida, T.; Atobe, K.; Wang, X.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection. *J. Control. Release* **2006**, *115*, 251–258. [[CrossRef](#)]
112. Ma, Y.; Yang, Q.; Wang, L.; Zhou, X.; Zhao, Y.; Deng, Y. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. *Eur. J. Pharm. Sci.* **2012**, *45*, 539–545. [[CrossRef](#)] [[PubMed](#)]
113. Bedocs, P.; Capacchione, J.; Potts, L.; Chugani, R.; Weiszhar, Z.; Szebeni, J.; Buckenmaier, C.C. Hypersensitivity reactions to intravenous lipid emulsion in swine: Relevance for lipid resuscitation studies. *Anesth. Analg.* **2014**, *119*, 1094–1101. [[CrossRef](#)] [[PubMed](#)]
114. Szebeni, J. Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. *Mol. Immunol.* **2014**, *61*, 163–173. [[CrossRef](#)] [[PubMed](#)]
115. Szebeni, J. Mechanism of nanoparticle-induced hypersensitivity in pigs: Complement or not complement? *Drug Discov. Today* **2018**, *23*, 487–492. [[CrossRef](#)] [[PubMed](#)]
116. Troelnikov, A.; Perkins, G.; Yuson, C.; Ahamdie, A.; Balouch, S.; Hurtado, P.R.; Hissaria, P. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. *J. Allergy Clin. Immunol.* **2021**, *148*, 91–95. [[CrossRef](#)]
117. Kozma, G.T.; Meszaros, T.; Vashegyi, I.; Fulop, T.; Orfi, E.; Dezsai, L.; Rosivall, L.; Bavli, Y.; Urbanics, R.; Mollnes, T.E.; et al. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. *ACS Nano* **2019**, *13*, 9315–9324. [[CrossRef](#)]
118. Elsadek, N.E.; Lila, A.S.A.; Emam, S.E.; Shimizu, T.; Takata, H.; Ando, H.; Ishima, Y.; Ishida, T. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. *Eur. J. Pharm. Biopharm.* **2020**, *152*, 56–62. [[CrossRef](#)]
119. Viegas, T.X.; Bentley, M.D.; Harris, J.M.; Fang, Z.F.; Yoon, K.; Dizman, B.; Weimer, R.; Mero, A.; Pasut, G.; Veronese, F.M. Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery. *Bioconjugate Chem.* **2011**, *22*, 976–986. [[CrossRef](#)]
120. Metselaar, J.M.; Bruin, P.; de Boer, L.W.T.; de Vringer, T.; Snel, C.; Oussoren, C.; Wauben, M.H.M.; Crommelin, D.J.A.; Storm, G.; Hennink, W.E. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. *Bioconjugate Chem.* **2003**, *14*, 1156–1164. [[CrossRef](#)]
121. Cao, J.; Chen, Y.W.; Wang, X.; Luo, X.L. Enhancing blood compatibility of biodegradable polymers by introducing sulfobetaine. *J. Biomed. Mater. Res. Part A* **2011**, *97A*, 472–479. [[CrossRef](#)]
122. Kong, Y.W.; Dreaden, E.C. PEG: Will It Come Back to You? Polyethylene Glycol Immunogenicity, COVID Vaccines, and the Case for New PEG Derivatives and Alternatives. *Front. Bioeng. Biotechnol.* **2022**, *10*, 879988. [[CrossRef](#)] [[PubMed](#)]
123. Shimizu, T.; Abu Lila, A.S.; Fujita, R.; Awata, M.; Kawanishi, M.; Hashimoto, Y.; Okuhira, K.; Ishima, Y.; Ishida, T. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. *Eur. J. Pharm. Biopharm.* **2018**, *127*, 142–149. [[CrossRef](#)] [[PubMed](#)]
124. Arvizo, R.R.; Miranda, O.R.; Moyano, D.F.; Walden, C.A.; Giri, K.; Bhattacharya, R.; Robertson, J.D.; Rotello, V.M.; Reid, J.M.; Mukherjee, P. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. *PLoS ONE* **2011**, *6*, e24374. [[CrossRef](#)] [[PubMed](#)]
125. Saifer, M.G.; Williams, L.D.; Sobczyk, M.A.; Michaels, S.J.; Sherman, M.R. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. *Mol. Immunol.* **2014**, *57*, 236–246. [[CrossRef](#)]
126. Khanna, P.P.; Khanna, D.; Cutter, G.; Foster, J.; Melnick, J.; Jaafar, S.; Biggers, S.; Rahman, A.; Kuo, H.C.; Feese, M.; et al. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis Rheumatol.* **2021**, *73*, 1523–1532. [[CrossRef](#)]
127. Ramot, Y.; Haim-Zada, M.; Domb, A.J.; Nyska, A. Biocompatibility and safety of PLA and its copolymers. *Adv Drug Deliv Rev* **2016**, *107*, 153–162. [[CrossRef](#)]

128. Thomasin, C.; Merkle, H.P.; Gander, B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 2. Parameters determining microsphere formation. *J. Pharm. Sci.* **1998**, *87*, 269–275. [[CrossRef](#)]
129. Danhier, F.; Ansorena, E.; Silva, J.M.; Coco, R.; Le Breton, A.; Preat, V. PLGA-based nanoparticles: An overview of biomedical applications. *J. Control. Release* **2012**, *161*, 505–522. [[CrossRef](#)]
130. Cabral, H.; Miyata, K.; Osada, K.; Kataoka, K. Block Copolymer Micelles in Nanomedicine Applications. *Chem. Rev.* **2018**, *118*, 6844–6892. [[CrossRef](#)]
131. Angelopoulou, A.; Voulgari, E.; Diamanti, E.K.; Gournis, D.; Avgoustakis, K. Graphene oxide stabilized by PLA-PEG copolymers for the controlled delivery of paclitaxel. *Eur. J. Pharm. Biopharm.* **2015**, *93*, 18–26. [[CrossRef](#)]
132. Chen, J.; Tian, B.; Yin, X.; Zhang, Y.; Hu, D.; Hu, Z.; Liu, M.; Pan, Y.; Zhao, J.; Li, H.; et al. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems. *J. Biotechnol.* **2007**, *130*, 107–113. [[CrossRef](#)]
133. Munier, S.; Messai, I.; Delair, T.; Verrier, B.; Ataman-Onal, Y. Cationic PLA nanoparticles for DNA delivery: Comparison of three surface polycations for DNA binding, protection and transfection properties. *Colloids Surf. B Biointerfaces* **2005**, *43*, 163–173. [[CrossRef](#)] [[PubMed](#)]
134. Yang, X.Z.; Dou, S.; Sun, T.M.; Mao, C.Q.; Wang, H.X.; Wang, J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. *J. Control. Release* **2011**, *156*, 203–211. [[CrossRef](#)]
135. Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; et al. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. *Bioconjug. Chem.* **2013**, *24*, 997–1007. [[CrossRef](#)] [[PubMed](#)]
136. Lv, G.; He, F.; Wang, X.; Gao, F.; Zhang, G.; Wang, T.; Jiang, H.; Wu, C.; Guo, D.; Li, X.; et al. Novel nanocomposite of nano Fe<sub>3</sub>O<sub>4</sub> and polylactide nanofibers for application in drug uptake and induction of cell death of leukemia cancer cells. *Langmuir* **2008**, *24*, 2151–2156. [[CrossRef](#)] [[PubMed](#)]
137. Zhou, W.; Zhou, C.; Meng, S.; Su, B.; Song, Y. The anti-tumor effects of lung cancer-targeting long-circulating paclitaxel-containing liposomes. *Tumor* **2011**, *31*, 203–209.
138. Sun, H.; Su, J.; Meng, Q.; Yin, Q.; Chen, L.; Gu, W.; Zhang, P.; Zhang, Z.; Yu, H.; Wang, S.; et al. Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors. *Adv. Mater.* **2016**, *28*, 9581–9588. [[CrossRef](#)]
139. Xin, H.; Sha, X.; Jiang, X.; Zhang, W.; Chen, L.; Fang, X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. *Biomaterials* **2012**, *33*, 8167–8176. [[CrossRef](#)]
140. Wang, Y.; Hao, J.; Li, Y.; Zhang, Z.; She, X.; Han, L.; Fang, X. Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxel-resistance in SKOV-3 tumors. *Biomaterials* **2012**, *33*, 4741–4751. [[CrossRef](#)]
141. Chen, M.S.; Chen, M.; He, J.T. Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA. *Artif. Cells Nanomed. Biotechnol.* **2019**, *47*, 1635–1641. [[CrossRef](#)]
142. Lohcharoenkal, W.; Wang, L.Y.; Chen, Y.C.; Rojanasakul, Y. Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy. *Biomed Res. Int.* **2014**, *2014*, 180549. [[CrossRef](#)] [[PubMed](#)]
143. Weber, C.; Coester, C.; Kreuter, J.; Langer, K. Desolvation process and surface characterisation of protein nanoparticles. *Int. J. Pharm.* **2000**, *194*, 91–102. [[CrossRef](#)] [[PubMed](#)]
144. Salatin, S.; Jelvehgari, M.; Maleki-Dizaj, S.; Adibkia, K. A sight on protein-based nanoparticles as drug/gene delivery systems. *Ther. Deliv.* **2015**, *6*, 1017–1029. [[CrossRef](#)] [[PubMed](#)]
145. Nehete, J.Y.; Bhambar, R.S.; Narkhede, M.R.; Gawali, S.R. Natural proteins: Sources, isolation, characterization and applications. *Pharmacogn. Rev.* **2013**, *7*, 107–116. [[CrossRef](#)]
146. Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. *J. Control. Release* **2012**, *157*, 168–182. [[CrossRef](#)]
147. Sleep, D. Albumin and its application in drug delivery. *Expert Opin. Drug Deliv.* **2015**, *12*, 793–812. [[CrossRef](#)]
148. Yewale, C.; Baradia, D.; Vhora, I.; Misra, A. Proteins: Emerging carrier for delivery of cancer therapeutics. *Expert Opin. Drug Deliv.* **2013**, *10*, 1429–1448. [[CrossRef](#)]
149. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. *J. Control. Release* **2008**, *132*, 171–183. [[CrossRef](#)]
150. Wu, Y.; Shih, E.K.; Ramanathan, A.; Vasudevan, S.; Weil, T. Nano-sized albumin-copolymer micelles for efficient doxorubicin delivery. *Biointerphases* **2012**, *7*, 5. [[CrossRef](#)]
151. Jiang, Y.; Lu, H.; Chen, F.; Callari, M.; Pourgholami, M.; Morris, D.L.; Stenzel, M.H. PEGylated Albumin-Based Polyion Complex Micelles for Protein Delivery. *Biomacromolecules* **2016**, *17*, 808–817. [[CrossRef](#)]
152. Liu, F.; Mu, J.; Xing, B. Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin. *Curr. Pharm. Des.* **2015**, *21*, 1866–1888. [[CrossRef](#)] [[PubMed](#)]
153. Sepehri, N.; Rouhani, H.; Ghanbarpour, A.R.; Gharghabi, M.; Tavassolian, F.; Amini, M.; Ostad, S.N.; Ghahremani, M.H.; Dinarvand, R. Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment. *Biomed. Res. Int.* **2014**, *2014*, 963507. [[CrossRef](#)] [[PubMed](#)]
154. Esmaeili, F.; Dinarvand, R.; Ghahremani, M.H.; Amini, M.; Rouhani, H.; Sepehri, N.; Ostad, S.N.; Atyabi, F. Docetaxel-albumin conjugates: Preparation, in vitro evaluation and biodistribution studies. *J. Pharm. Sci.* **2009**, *98*, 2718–2730. [[CrossRef](#)] [[PubMed](#)]
155. Wu, Y.; Ng, D.Y.; Kuan, S.L.; Weil, T. Protein-polymer therapeutics: A macromolecular perspective. *Biomater. Sci.* **2015**, *3*, 214–230. [[CrossRef](#)] [[PubMed](#)]

156. Jiang, Y.; Stenzel, M. Drug Delivery Vehicles Based on Albumin-Polymer Conjugates. *Macromol. Biosci.* **2016**, *16*, 791–802. [[CrossRef](#)]
157. Dag, A.; Jiang, Y.; Karim, K.J.; Hart-Smith, G.; Scarano, W.; Stenzel, M.H. Polymer-albumin conjugate for the facilitated delivery of macromolecular platinum drugs. *Macromol. Rapid Commun.* **2015**, *36*, 890–897. [[CrossRef](#)]
158. Liu, Z.; Dong, C.; Wang, X.; Wang, H.; Li, W.; Tan, J.; Chang, J. Self-assembled biodegradable protein-polymer vesicle as a tumor-targeted nanocarrier. *ACS Appl. Mater. Interfaces* **2014**, *6*, 2393–2400. [[CrossRef](#)]
159. Tang, B.; Qian, Y.; Gou, Y.; Cheng, G.; Fang, G.H. VE-Albumin Core-Shell Nanoparticles for Paclitaxel Delivery to Treat MDR Breast Cancer. *Molecules* **2018**, *23*, 2760. [[CrossRef](#)]
160. Shen, Y.Z.; Li, W.T. HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. *Drug Des. Dev. Ther.* **2018**, *12*, 2285–2292. [[CrossRef](#)]
161. Reddy, N.; Rapisarda, M. Properties and Applications of Nanoparticles from Plant Proteins. *Materials* **2021**, *14*, 3607. [[CrossRef](#)]
162. Lee, H.S.; Kang, N.W.; Kim, H.; Kim, D.H.; Chae, J.W.; Lee, W.; Song, G.Y.; Cho, C.W.; Kim, D.D.; Lee, J.Y. Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel. *Carbohydr. Polym.* **2021**, *253*, 117187. [[CrossRef](#)] [[PubMed](#)]
163. Gulfam, M.; Kim, J.E.; Lee, J.M.; Ku, B.; Chung, B.H.; Chung, B.G. Anticancer Drug-Loaded Gliadin Nanoparticles Induce Apoptosis in Breast Cancer Cells. *Langmuir* **2012**, *28*, 8216–8223. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.